ladarixin
Small moleculeexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01571895)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor AMODULATOR
CXCR1 modulator
Ph 2 study terminated, being developed for new indication (http://www.dompe.com/Diabetology/).
- Interleukin-8 receptor BMODULATOR
CXCR2 modulator
Ph 2 study terminated, being developed for new indication (http://www.dompe.com/Diabetology/).
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1- Mol. weight
- 375.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL189475 ↗
Also known as
- 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-n-methanesulfonylpropionamide
- df2156a
- df2156a
- df2156a
- df 2156a
- df-2156a
- df-2156a
- df-2156a
- df2156y
- df 2156y
- df-2156y
- ladarixin
- ladarixin
- ladarixin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05815186 | Phase 2 | Apr 30, 2024 | New York University |
| NCT05815173 | Phase 1 | Aug 1, 2023 | New York University |
| NCT05368402 | Phase 2 | Jul 27, 2022 | Dompe Pharmaceuticals |
| NCT05035368 | Phase 2 | Sep 30, 2021 | Dompe Pharmaceuticals, University of Pennsylvania |
| NCT04628481 | Phase 3 | Dec 31, 2020 | Dompe Pharmaceuticals |
| NCT04899271 | Phase 2 | Dec 14, 2020 | Dompe Pharmaceuticals |
| NCT04854642 | Phase 1 | Oct 20, 2020 | Cross Research S.A., Dompe Pharmaceuticals |
| NCT02814838 | Phase 2 | Aug 1, 2016 | Dompe Pharmaceuticals, University of Milan |
| NCT01571895 | Phase 2 | Jul 1, 2011 | Dompe Pharmaceuticals, Istituto Dermopatico dell'Immacolata, Roma |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dompe Pharmaceuticals | For profit | 7 | 7 | 3 | 2011 |
| New York University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2020 |
| Istituto Dermopatico dell'Immacolata, Roma | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1